TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Mangoceuticals, Inc. ( (MGRX) ) is now available.
On November 13, 2025, Mangoceuticals, Inc. clarified its earlier announcement regarding the launch of its weight-management programs, MangoRx Direct and PeachesRx Direct. These programs are licensed to issue prescriptions for FDA-approved GLP-1 medications from Eli Lilly and Novo Nordisk, providing patients access to these medications through Mangoceuticals’ platform. The programs offer telehealth consultations and personalized care plans, enhancing the company’s position in the telemedicine and weight management industry.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc. is focused on developing men’s health and wellness products and services through a telemedicine platform. The company targets the growing sector of men’s wellness, particularly in areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management.
Average Trading Volume: 1,301,207
Technical Sentiment Signal: Sell
Current Market Cap: $18.54M
For detailed information about MGRX stock, go to TipRanks’ Stock Analysis page.